Intranasal ketamine promising for treatment-resistant major depression
Results from a newly published study indicate that intranasal ketamine spray can produce a rapid and sustained antidepressant effect within 24 hours, and was well tolerated in a small group of patients with treatment-resistant major depressive disorder. This is the first study to show benefits with an intranasal formulation of ketamine. Previous research has indicated that intravenous ketamine may have a role in helping patients with major depressive disorder and suicidal ideation.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063